 Home > Pharmaceutical Intermediates > Metabolic Bone Disease > Ezetimibe for Sale > Ezetimibe API - A Selective Cholesterol Absorption Inhibitor for Lipid Control.

Ezetimibe API - A Selective Cholesterol Absorption Inhibitor for Lipid Control. buy - large image1

Ezetimibe API - A Selective Cholesterol Absorption Inhibitor for Lipid Control. buy - image1

Ezetimibe API - A Selective Cholesterol Absorption Inhibitor for Lipid Control. buy - image2

Ezetimibe API - A Selective Cholesterol Absorption Inhibitor for Lipid Control.

Name: Ezetimibe API - A Selective Cholesterol Absorption Inhibitor for Lipid Control.
Brand: Tianrui
SKU: pr2511131361
Price: 11 USD
Availability: InStock

6 Inquiries

Unit Price: Get Latest Price 

CAS No.:

163222-33-1

Grade:

Pharmaceutical Grade

Content:

101%

Port:

Qingdao

Brand:

Tianrui

Packaging:

Sealed fiber drum

Price valid (until):

2025-11-12

Contact Supplier

 Chat Now

Hefei Tianrui Pharmaceutical Chemical Co., Ltd.

Company Type:

Manufactory

Location:

China

Qualification:

Main Products:

APIs

 Visit Store

Product Description
Seller Information
Inquiry History

Description

About Product

Ezetimibe (CAS: 163222-33-1) is a high-purity, chiral active pharmaceutical ingredient (API) that functions as a selective cholesterol absorption inhibitor. It acts at the brush border of the small intestine to block the absorption of dietary and biliary cholesterol, offering a unique mechanism complementary to statin therapy. Manufactured by Hefei TianRui Pharmaceutical under strict cGMP conditions, our Ezetimibe API guarantees high chiral purity, excellent stability, and reliable quality for lipid-lowering formulations.

Items	Specifications
Product Name	Ezetimibe
CAS Registry Number	163222-33-1
IUPAC Name	(3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one
Molecular Weight	409.43 g/mol
Solubility	It is slightly soluble in methanol and ethanol, and almost insoluble in water.
Primary Use	Primary hypercholesterolemia Homozygous familial hypercholesterolemia Squaleneemia

Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 1

Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 2

Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 3

Company Profile

Founded: 2014
Focus: High-tech enterprise specializing in the development and industrialization of small-molecule pharmaceutical synthesis technology
Facilities:
- Two workshops (TR1 & TR2) with total capacity ≈ 1000 tons/year
- Reactors: 3000L×15, 2000L×10, and numerous smaller reactors (1000L, 500L, 100L)
- Ultra-low temperature cryogenic reactor (explosion-proof workshop included)
- GMP workshop & clean room
QC Lab Equipment: GC×2, HPLC×3, UV, IR, KF titrator, etc.

About company

Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 7

In 2015, the company developed polypeptide absorbent permeation enhancers: ethyl 8-bromo-octanoate and Carsalam, which is the 1st and only qualified Chinese supplier of Semaglutide to meet the internal control requirements of innovator Novo Nordisk.

In 2020, the company independently developed and optimized 8-bromo-octanoic acid and 6-bromo-caproic acid to become a COVID-19 vaccine carrier manufacturer and supplier to Moderna company, contributing its share to the fight against COVID-19.

In 2022, Tianrui R&D Center and cGMP manufacturing facility was inaugurated and put into operation. And in the same year, polypeptide absorbent permeation enhancers SNAC (Salcaprozate Sodium) has successfully obtained the domestic CDE registration number (F20220000072) and the US FDA registration number (037135), and another batch of innovative APIs and pharmaceutical excipients are under registration and approval.

Basic Info

Product Name:

Ezetimibe

Other Name:

2-Azetidinone,1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-,(3R,4S)-;2-Azetidinone,1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-,[3R-[3α(S*),4β]]-;(3R,4S)-1-(4-Fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone;Sch 58235;Ezetimibe;(-)-Sch 58235;Zetia;Ezetrol;Ezta;Ezedoc;1-(4-Fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)azetidin-2-one;Ezentia

CAS No.:

163222-33-1

Molecular Formula:

C24H21F2NO3

InChIKeys:

InChIKey=OLNTVTPDXPETLC-XPWALMASSA-N

Molecular Weight:

409.43

Exact Mass:

409.43

EC Number:

1308068-626-2

UNII:

EOR26LQQ24

DSSTox ID:

DTXSID1044223

NCI Thesaurus Code:

C47529

Color/Form:

White solid

ATC Code:

C10B|C10AX09|C - Cardiovascular system

HScode:

29337900

Categories:

Metabolic Bone Disease

Characteristics

PSA:

60.8

XLogP3:

Appearance:

Solid

Density:

1.334±0.06 g/cm3(Predicted)

Melting Point:

164-166 °C

Boiling Point:

654.9±55.0 °C(Predicted)

Flash Point:

349.9±31.5 °C

Refractive Index:

1.624

Water Solubility:

H2O: Insoluble

Storage Conditions:

-20°C Freezer

Vapor Pressure:

1.5X10-14 mm Hg at 25 deg C (est)

Specific rotation:

D22 -33.9° (c = 3 in methanol)

Henrys Law Constant:

Henry's Law constant = 4.4X10-18 atm-cu m/mole at 25 °C (est)

Dissociation Constants:

pKa1 = 9.73 (phenol) (est)

Collision Cross Section:

213.6 Å² [M+Na]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

See More Ezetimibe Properties 

Hazard Identification

Classification of the substance or mixture

Hazardous to the aquatic environment, long-term (Chronic) - Category Chronic 1

GHS label elements, including precautionary statements

Precautionary statement(s)
Pictogram(s)
Signal word	Warning
Hazard statement(s)	H410 Very toxic to aquatic life with long lasting effects
Prevention	P273 Avoid release to the environment.
Response	P391 Collect spillage.
Storage	none
Disposal	P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

Other hazards which do not result in classification

no data available

Handling and Storage

Precautions for safe handling

Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

Conditions for safe storage, including any incompatibilities

Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

See More Ezetimibe Safety Data Sheet 

Seller Information

Business Type:
Manufactory

Main Products:
APIs

Location:
No.23,lntersection of Fenglehe Avenue and Leiyang Road, Huagang Town,Feixi County, Hefei, Anhui, China.

Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

Average lead Time:
15

Total Annual Revenue:
$50 million-$100 million

Total Employees:
11-50

Year of Establishment:
2014

About TianRui

Hefei TianRui Pharmaceutical Chemical Co., Ltd was founded in 2014 as a high-tech enterprise focused on the development and industrialization of pharmaceutical small molecule synthesis technology. Our workshop and R&D center are located in Hefei HuaGang Provincial Industrial Park, Anhui Province. We are committed to providing professional technical services and commercialization of small molecule specialty APIs, CGMP standard intermediates, and functional pharmaceutical excipients and MRNA vaccine vectors for domestic and overseas well-known pharmaceutical companies.

Main Events

In 2015, the company developed polypeptide absorbent permeation enhancers: ethyl 8-bromo-octanoate and Carsalam, which is the 1st and only qualified Chinese supplier of Semaglutide to meet the internal control requirements of innovator Novo Nordisk.

In 2020, the company independently developed and optimized 8-bromo-octanoic acid and 6-bromo-caproic acid to become a COVID-19 vaccine carrier manufacturer and supplier to Moderna company, contributing its share to the fight against COVID-19.

In 2022, Tianrui R&D Center and cGMP manufacturing facility was inaugurated and put into operation. And in the same year, polypeptide absorbent permeation enhancers SNAC (Salcaprozate Sodium) has successfully obtained the domestic CDE registration number (F20220000072) and the US FDA registration number (037135), and another batch of innovative APIs and pharmaceutical excipients are under registration and approval.

Inquiry History

6 Inquiries

Country	Product	Purchase Quantity	Date Posted
India	Ezetimibe	5.00 KG	Jan 22, 2024
Pakistan	Ezetimibe	10 KG	Oct 29, 2025
United States	Ezetimibe	10 G	Sep 16, 2025
United States	Zetia ,Combivent ,Symbicort ,Namenda ,NovoLog FlexPen , Xarelto ,NovoLog ,Humalog , Suboxone ,	60 MT	Oct 12, 2023
India	Linagliptin	5.00 KG	Jan 22, 2024
India	Febuxostat	5.00 KG	Jan 22, 2024

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Supplier Name	Details
API raw material Ezetimibe	Pharmaceutical Grade/99		Inquiry
Ezetimibe	/	bazayan Enterprises LLP	Inquiry
Ezetimibe CAS:163222-33-1	/	Jiangsu Hansyn Pharmaceutical Co.,Ltd	Inquiry
Ezetimibe	/	Hangzhou Dawn Ray Pharmaceutical Co.,Ltd	Inquiry
High Quality 99% White Powder Ezetimibe CAS 163222-33-1 with good price and fast delivery	Pharmaceutical Grade/99	Hangzhou Hyper Chemicals Limited	Inquiry